PGS13: DIFFERENCES BETWEN ELDERLY AND YOUNGER ADULTS IN THE EPIDEMIOLOGY AND TREATMENT OF SYMPTOMATIC GERD AND NOCTURNAL GERD  by Ricci, JA et al.
249Abstracts
proportion was signiﬁcantly higher in males than females
(25.7% vs. 20.0%, p < 0.001). Overall mean age was
45.84 (IP 46.64; OP 45.62, p < 0.001). Proportion of 
IP among all LCs was signiﬁcantly higher among older
people (18–34y: 20.4%; 35–44y: 19.9%; 45–54y:
20.2%; 55–65y: 24.7%, p < 0.001). IP proportions by
diagnosis were: calculus of the gall bladder and/or bile
duct, 31.8%; other gall bladder disorders (including
cholecystitis), 13.9%; diseases of the pancreas, 87.6%;
and all other diagnoses, 41.3% (p < 0.001). Mean net
cost for LC hospital admission was $9168 (95% CI:
$8913–$9424) and average LOS was 3.6 days (95% CI:
3.4–3.8). Net OP procedure cost for LC was $3158 (95%
CI: $3123–$3194). CONCLUSIONS: Nearly 80% of
LCs in the US managed care population were ambulatory-
based. Patients undergoing IP LC were signiﬁcantly dif-
ferent from patients undergoing OP LC in age, gender,
and primary diagnosis. Cost of hospital-based LC was
almost three times higher than cost of ambulatory-based
LC.
PGS12
COST-MINIMIZATION ANALYSIS OF A
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OBJECTIVE: Several medications are equally efﬁcacious
regardless of dosage form. This study conducted a cost-
minimization analysis from an institutional perspective 
of a pharmacist-directed intravenous to oral conversion
program for pantoprazole, a proton pump inhibitor (PPI).
Empirical evidence supports equivalence of IV and tablet
forms of pantoprazole in inhibiting gastric acid secretion.
METHODS: Patients on IV pantoprazole in select units
at a tertiary care teaching hospital between March 15,
2002 and April 12, 2002 were included in the interven-
tion group. Following a protocol approved by the Phar-
macy & Therapeutics Committee, a pharmacist evaluated
patients to determine eligibility for conversion to admin-
istration by mouth or nasogastric tube. The pharmacist
recorded times required to identify and switch patients.
Average times required for preparation, dispensing, and
administration of dosage forms were determined via
employee interview. Medication acquisition and labor
costs were obtained from the hospital ﬁnancial depart-
ment. Proportion of days therapy with each dosage form
for the intervention group and historical control group,
which otherwise met identical inclusion criteria, were
determined from the pharmacy database. RESULTS: A
signiﬁcant difference in proportion of days therapy with
PPI dosage forms existed between control (N = 182) and
intervention (N = 150) groups (C2 = 276.39, df = 2, p <
0.05). The intervention increased total proportion of days
therapy with pantoprazole tablets and PPI suspensions by
6.9% and 22.0%, respectively. Days therapy with IV 
pantoprazole were decreased by 28.8% (from 61.2% to
32.4%). Applying costs for medications, supplies, and
labor, the conversion program saves $13.45/patient
started on IV pantoprazole. Projecting cost saving to 1
year with 1887 patients/year, the conversion program
could save $25,380.15 in the hospital budget. CON-
CLUSION: A pharmacist-directed intravenous to oral
dosage form conversion program can result in institu-
tional cost savings. However, cost savings are dependent
on success in converting patients. Cost savings would 
be increased to $18.50/patient on IV pantoprazole by
shifting an additional 6.9% of PPI therapy days from IV
pantoprazole to pantoprazole tablets.
GASTROINTESTINAL DISEASES/DISORDERS—
Quality of Life/Preference Based Outcomes
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OBJECTIVE: To compare the epidemiology and treat-
ment of GERD and nocturnal GERD in a U.S. national
sample of elderly (65+ years of age) and younger adults
(<65 years of age). METHODS: A national random-
sample phone survey of 9035 adults identiﬁed 171 elderly
and 1090 younger adults with symptomatic GERD, and
42 elderly and 329 younger adults with nocturnal GERD.
Symptomatic GERD cases reported heartburn or regurgi-
tation 1+ time/week in past three months. Nocturnal
GERD was deﬁned as symptomatic GERD with 1+
nocturnal symptom 1+ time/week. Severe was deﬁned as
2+ episodes/week. The interview included questions on
symptom frequency, concomitant motility-related symp-
toms, and treatment for GERD symptoms. Chi-square
tested for statistical signiﬁcance between elderly and
younger adults. RESULTS: Prevalence of symptomatic
GERD (9.9% vs. 14.9%; p < 0.0001) and nocturnal
GERD (2.4% vs. 4.5%; p < 0.0001) was lower and less
severe (74% vs. 87%; p < 0.05) in elderly than younger
adults. Most bothersome symptoms were regurgitation in
elderly, and heartburn in younger adults. Among GERD
cases, motility-related symptoms (e.g., post-prandial full-
ness, early satiety) were less prevalent or less frequent in
the elderly than younger adults. Among nocturnal GERD
cases, prevalence of motility-related symptoms was not
different between elderly and younger adults, but the
elderly reported less severe post-prandial fullness (p <
0.05) and a lower frequency of nausea (p < 0.001) than
younger adults. Prescription medication use for GERD-
related symptoms was reported by 24% of nocturnal
GERD cases and did not differ by age. However, elderly
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nocturnal GERD cases reported less non-prescription
medication use than younger adults (9.5% versus 22.5%;
p < 0.05) for GERD-related symptoms. CONCLUSIONS:
Symptomatic GERD and nocturnal GERD were less
prevalent and severe in elderly compared to younger
adults. Elderly reported less medication use for GERD-
related sysptoms than younger adults.
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GASTROESOPHAGEAL REFLUX IN INFANTS:
IMPACT ON THE QOL OF PARENTS
Taïeb C, Marionneau N, Myon E
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Very common in infants, gastroesophageal reﬂux causes
regurgitations which generally disappear during the ﬁrst
year of life (or before the infant starts walking). Diagno-
sis was made in 18% of cases during a statistical study
carried out among infants which were theoretically in
good health. Although rarely or not at all evaluated, the
impact of GER in infants upon the everyday life of the
parents is undoubtedly far from negligible. OBJECTIVE:
To evaluate the impact of GER in infants upon the quality
of life of both parents. METHODS: Within the context
of a cohort, 150 infants (under 3 months of age) were
monitored over a period of 6 months. On inclusion, a
generic scale (SF-12) are completed by both parents. The
completed questionnaires were returned in prepaid en-
velopes. RESULTS: The ﬁrst results concerned the ﬁrst 40
patients. Regarding the SF-12, the results were organised
in 2 scores: mental (MCS-12) and physical (PCS-12). The
norms observed in a standard American population are a
score of 50 (e-t:10) for each dimension. The SF-12 scores
for the fathers on inclusion were: PCS-12 = 52.6 (4.5) &
MCS-12 = 44.7 (8.4). The SF-12 scores for the mothers
on inclusion were: PCS-12 = 47.4 (7.7) & MCS-12 = 36.0
(9.8). Paired comparison of these results shows a modiﬁ-
cation in the quality of life of the mother compared with
that of the father. This difference is signiﬁcant in both
dimensions (p < 0.005). CONCLUSIONS: The quality of
life, evaluated by the SF12, of the parents whose child
suffered from gastroesophageal reﬂux was modiﬁed; this
phenomenon was particularly marked with regard to the
‘‘mental’’ component. The quality of life of the mother
was, in our study, more modiﬁed than that of the father.
The impact upon the quality of life of the immediate
entourage was, once again, highlighted. This impact
should be taken into consideration in the treatment of the
infant.
INFECTION—Clinical Outcomes/Healthcare Policy
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OBJECTIVE: To determine whether there is association
between skin tattoos, Hepatitis-B and prisons, to investi-
gate risk behaviors for Hepatitis-B and to describe 
characteristics of person who have tattoos. METHODS:
This retrospective study consisted of a self-administered
survey, and an ELISA blood test for viral hepatitis B. The
study sample consisted of all 1/2001 privates at Adisorn
Fort Hospital Saraburi who had tattoos (n1 = 46) and
simple random sampling of another group of 46 volun-
teer privates who did not have tattoos. RESULTS: All pri-
vates (N = 92) were male, age 22.88b 1.41 years, 67
(72.8%) had graduated from elementary and high school,
29 were positive for Hepatitis-B antibodies (31.5%), 41
(44.6%) had sex with prostitutes, 3 (3.3%) did not 
use condom, 4 (4.3%) shared razors, 1 (1.1%) shared
needles, 25 (27.2%) had been in jail, 87 (94.6%) drank
alcohol, 43 (46.7%) had used amphetamines. Twenty
(28.6%) had tattoos on 2 arms. Ten (14.3%) had tattoo
on their back, 9 (19.6%) obtained their tattoos while in
prison, 15 (32.6%) had a tattoo that was greater than
20% of the body’s surface area. There was an association
between skin tattoo and Hepatitis B (Chi Square, p < .01,
OR: 15 :9, 95%CI: 1.97–128.16), and an association
between skin tattoo and having been in prison (Chi
Square, p < .01, OR: 6.3, 95%CI: 2.1–18.8), There was
no association between having been in jail and Hepatitis-
B. Logistic regression was employed to ﬁnd factors for
Hepatitis-B. The variables that were associated with
Hepatitis-B (<.05) were entered procedure to identify
association with Hepatitis-B. Hit rate was 87.9, Pseudo
R Square 0.464, Skin tattoos, a history of a family
member with Hepatitis-B, and sharing needles increased
the chance of getting Hepatitis-B. CONCLUSIONS:
There were associations between jails and tattoos and
viral hepatitis-B. Hygiene in tattoo’ shops should be con-
trolled by the government.
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OBJECTIVE: To compare the clinical efﬁcacy, AECB-
related hospitalization rates, and length of stay in hospi-
tal (LOS) in outpatients with AECB treated with either
TEL or AMC. METHODS: Outpatients with AECB 
(n = 325) were enrolled in a randomized, double-blind,
double-dummy, multicenter clinical study and received
either oral TEL 800mg once daily for 5 days or AMC
500/125mg 3 times daily for 10 days. Clinical and eco-
nomic outcomes were followed for 4 weeks. The primary
